MyFinsight
Home
Blog
About
Contact
Download
Download image
Change in cash and cash
equivalents for the period
-$17,756,950
Share-based payments
$3,240,107
Prepaids
-$286,517
Accrued investment
income
-$89,126
Amortization of right-of-use
asset
$63,836
Accretion of lease
liability
$19,819
Proceeds from short-term
investments sold
$29,225,000
Net cash used in
operating activities
-$17,518,819
Net cash provided by
(used in) investing...
-$238,131
Canceled cashflow
$3,699,405
Canceled cashflow
$29,225,000
Net loss for the
period
-$18,909,992
Purchase of short-term
investments
$29,463,131
Accounts payable and
accrued liabilities
-$1,577,018
Accretion of
premiums/discounts on short-term...
$501,314
Receivables
$112,456
Operating lease liability
-$85,796
Termination of lease (note 7)
$31,648
Back
Back
Cash Flow
source: myfinsight.com
ESSA Pharma Inc. (EPIX)
ESSA Pharma Inc. (EPIX)